Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Depreciation & Amortization (2016 - 2025)

Northwest Biotherapeutics' Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at -$16.8 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at -$16.8 million for Q4 2025, down 1045.53% from a year ago — trailing twelve months through Dec 2025 was -$16.8 million (down 1045.53% YoY), and the annual figure for FY2025 was -$16.8 million, down 1045.53%.
  • Accumulated Depreciation & Amortization for Q4 2025 was -$16.8 million at Northwest Biotherapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.8 million in Q4 2024 to a low of -$16.8 million in Q2 2023.
  • The 5-year median for Accumulated Depreciation & Amortization is $703500.0 (2023), against an average of -$3.6 million.
  • The sharpest move saw Accumulated Depreciation & Amortization crashed 1310.15% in 2022, then soared 250.49% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.1 million in 2021, then crashed by 1310.15% to -$13.1 million in 2022, then skyrocketed by 103.86% to $507000.0 in 2023, then soared by 250.49% to $1.8 million in 2024, then tumbled by 1045.53% to -$16.8 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at -$16.8 million, $1.3 million, and $900000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.